Oritavancin - Melinta Therapeutics

Drug Profile

Oritavancin - Melinta Therapeutics

Alternative Names: LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate; Ramvocid

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer The Medicines Company
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacteraemia
  • Phase I Gram-positive infections
  • Discontinued Anthrax; Clostridium-difficile-infections

Most Recent Events

  • 01 Oct 2018 Oritavancin sub-licensed to Menarini group in Europe, Asia-Pacific, China, South Korea, Australia and the Commonwealth of Independent States including Russia
  • 29 Jan 2018 Phase I development in Gram-positive-infections (In adolescents, In children) is ongoing in USA (IV, Infusion) (NCT02134301)
  • 29 Jan 2018 Discontinued - Preclinical for Anthrax in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top